| __timestamp | Bristol-Myers Squibb Company | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 35942000 |
| Thursday, January 1, 2015 | 5001000000 | 40028000 |
| Friday, January 1, 2016 | 5002000000 | 45853000 |
| Sunday, January 1, 2017 | 4849000000 | 53816000 |
| Monday, January 1, 2018 | 4551000000 | 60804000 |
| Tuesday, January 1, 2019 | 4871000000 | 77252000 |
| Wednesday, January 1, 2020 | 7661000000 | 45736000 |
| Friday, January 1, 2021 | 7690000000 | 50323000 |
| Saturday, January 1, 2022 | 7814000000 | 143526000 |
| Sunday, January 1, 2023 | 7772000000 | 149182000 |
| Monday, January 1, 2024 | 8414000000 | 154335000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Bristol-Myers Squibb Company and Halozyme Therapeutics, Inc., from 2014 to 2023.
Bristol-Myers Squibb, a giant in the pharmaceutical sector, has consistently allocated a significant portion of its budget to SG&A expenses, peaking at approximately $7.8 billion in 2022. This represents a 37% increase from its lowest point in 2018. In contrast, Halozyme Therapeutics, a smaller yet innovative company, has seen its SG&A expenses grow by over 300% during the same period, reaching nearly $149 million in 2023.
This stark contrast highlights the differing scales and strategies of these companies, offering insights into their operational priorities and market positioning.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Bristol-Myers Squibb Company
Operational Costs Compared: SG&A Analysis of Novartis AG and Halozyme Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Biogen Inc.
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Verona Pharma plc
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Alkermes plc
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs CRISPR Therapeutics AG Trends and Insights
Bristol-Myers Squibb Company or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Perrigo Company plc
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Halozyme Therapeutics, Inc. Trends and Insights
Halozyme Therapeutics, Inc. vs Mesoblast Limited: SG&A Expense Trends